All the bisphosphonate are same?

CHENG Qun,ZHU Hanmin

DOI: https://doi.org/10.3969/j.issn.1006-7108.2010.5.016

2010-01-01

Abstract:Bisphosphonates are a chemical class of compounds in widespread use for the management of disorders of bone metabolism. The members of this drug class share a common P-C-P backbone structure,which act as a "bone hook" and is essential for binding to hydroxyapatite and exert differential actions within osteoclasts. The unique structure of each bisphosphoate determines its efficacy and relative utility in treating specific disorders of bone resorption. The R side group predominantly determines the antiresorptive potency of the bisphophonates and has some effect on binding. The presence of nitrogen groups within the R side group is associated with the ability of an individual bisphosphonate to inhibit farnesyl pyrophosphate (FPP) synthase,a major enzyme in the mevalonate pathway. Structural differences among bisphophonates explain the observed differences in mineral binding and antiresorptive potency and may in turn account for some of the clinical differences that have been seen in potency,duration of effect,and antifracture efficacy among members of this drug class. These structure-function variations may account for the differences observed in the outcomes of clinical efficacy trials,particularly in antifracture effects. Several major trial have contributed to our current understanding of the impact of bisphophonates in osteoporosis,including the Fracture Intervention Trial (FIT),the Vertebral Efficacy with Risedronate Therapy trial (VERT),and the Oral Ibandronate Osteoporosis Vertebral Fracture in North America and Europe (BONE). Clinical trial data,have shown that risedronate and alendronate reduce the risk of vertebral and nonvertebral fractures as early as 6 months ( risedronate) and 12 months ( alendronate ). In contrast to risedronate and alendronate,ibandronate only reduces the risk of vertebral fractures,with no evidence for its efficacy in hip and nonvertebral fracture reduction. The antifracture efficacy of different bisphophonates ideally should be compared via head-to-head comparisons in fracture endpoint trials.